Matches in Nanopublications for { ?s ?p "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP1158012.RAWah3oanEN_Eb2Zs76wLlXBwfKI0RbVoBQLzzDNz_1Ck130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158012.RAWah3oanEN_Eb2Zs76wLlXBwfKI0RbVoBQLzzDNz_1Ck130_provenance.
- NP1158007.RAsfWSXddeh25joVAmCilEIUBW6wX9sfJx7_WULmCk42c130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158007.RAsfWSXddeh25joVAmCilEIUBW6wX9sfJx7_WULmCk42c130_provenance.
- NP1158016.RArKfKitoM1VlKNLOwkdelEEOPV_hhnxIEn3YDQ-zshC4130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158016.RArKfKitoM1VlKNLOwkdelEEOPV_hhnxIEn3YDQ-zshC4130_provenance.
- NP1158020.RAme896aTbIKFazdsqEdFFdlusxoF9k20KwyubdXRqH4Y130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158020.RAme896aTbIKFazdsqEdFFdlusxoF9k20KwyubdXRqH4Y130_provenance.
- NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158025.RArfsZ3_7f7s47tvT8wFv-vC4BF7zKK9CEVzp3_PyCuRU130_provenance.
- NP1158010.RAPI-s4j9AzxlzNbLNQC6Jl-wCRu64-IlaOI2h1CH9fUc130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158010.RAPI-s4j9AzxlzNbLNQC6Jl-wCRu64-IlaOI2h1CH9fUc130_provenance.
- NP1158008.RA8MuFTAC3JXv9PF8FTlk4e6WwPd6ol26HeSOIQyRODlg130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158008.RA8MuFTAC3JXv9PF8FTlk4e6WwPd6ol26HeSOIQyRODlg130_provenance.
- NP1158017.RA0JRRfEwRDJArsTjfkLjqJWe3U1sbEqaKB5rCi8-r0kc130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158017.RA0JRRfEwRDJArsTjfkLjqJWe3U1sbEqaKB5rCi8-r0kc130_provenance.
- NP1158024.RA9sVH7toDI-YthStddyO_chNAzgCbxFRKdw0BfnnvyCg130_assertion description "[Given that p38 inhibitors are in clinical use for inflammatory disorders, GALR2/p38-mediated cytokine secretion may be an excellent target for new adjuvant therapy in SCCHN.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1158024.RA9sVH7toDI-YthStddyO_chNAzgCbxFRKdw0BfnnvyCg130_provenance.